Published on September 25, 2009 by

The Affordable Medicines Facility-malaria (AMFm): The Global Fund’s approach to combating Malaria in the developing world

Malaria remains a leading cause of morbidity and mortality in the developing world. In sub-Saharan Africa most countries have changed their treatment policies from chloroquine or Sulfadoxine-Pyrimethamine-based monotherapy to artemisinin-based combination therapy (ACT). However, it is suggested that an expanded access to effective treatment is also needed in order to “gain ground” against malaria. The Affordable Medicines Facility-malaria (AMFm) from the Global Fund aims to reduce the price of ACTs through an innovative approach of buyer co-payment.